Reported 3 days ago
Eli Lilly's stock is gaining traction as recent clinical trial data suggests its anti-obesity drug, Zepbound, outperforms Novo Nordisk's Wegovy in effectiveness, achieving an average weight loss of 20.2% compared to 13.7%. This significant advantage may enhance Zepbound's market share as it facilitates sales growth, projected to add around $100 million in quarterly revenue as more data becomes available. Despite its high valuation, investing in Lilly remains an attractive opportunity, though caution is advised.
Source: YAHOO